sur GENOWAY (EPA:ALGEN)
Half-year results 2024: genOway achieves its growth objectives
The biotechnology company genOway has announced a +15% growth in its turnover, reaching €10.7 million for the first half of 2024. The results confirm the objectives of the ROUTE50+ strategic plan.
The EBITDA margin stood at 18.7%, well above the profitability threshold of 15%. Net income, however, shows a slight decline, from €1.0 million in 2023 to €0.7 million in 2024. Available cash amounts to €4.9 million, allowing genOway to finance its investments in recruitment and R&D.
The company plans to increase its workforce by 20% and step up its R&D spending to develop new models. Annual growth prospects are set at +20%, with a revenue target of €50 million by 2028.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de GENOWAY